Established with the goal of addressing the significant health issue of ED, LTR Pharma has introduced SPONTAN®, a first-in-class intranasal PDE5 inhibitor designed to work rapidly within 10 minutes. This approach is intended to provide a more spontaneous and less invasive treatment compared to traditional methods. The company went public with an initial public offering in December 2023, raising AUD 7 million to advance this product.
LTR Pharma Limited (ASX:LTP)
A Clinical Stage Biopharmaceutical Company
About Us
LTR Pharma is an Australian clinical-stage biopharmaceutical company headquartered in Brisbane, focusing on developing innovative treatments for ED, notably through its intranasal delivery system, SPONTAN®.
Company Overview
Board & Management
Lee Rodne
Executive Chairman
Lee holds over 25 years’ experience in healthcare and technology sectors in both public ASX and private enterprises, holding multiple executive leadership roles.
Prior to joining LTR Pharma, Lee worked at Fortescue Metals group and was CEO and managing director for healthcare technology spin out Allied Medical, leading it to a valuation peak of $250m from $800k.
Lee has a proven record of commercialising medical devices in Australia, North America, Europe and Asia with significant experience in Nasal Spray product sales
Dr Julian Chick
Independent Non-Executive Director
Julian is an experienced healthcare executive with over 20 years’ experience in board and senior management positions, including ASX listed companies Avexa (ASX.AVX), Admedus (ASX.AHZ), and is current Deputy Chairman of Cann Group Limited (ASX:CAN).
Julian’s experience includes working across investment banking transactions for over eight years, focused on reviewing healthcare and biotechnology investment opportunities for private equity investors and venture capitalists.
Maja McGuire
Independent Non-Executive Director
Maja is a consulting lawyer and board director with a 15-year track record of providing strategic, corporate and compliance advice to public listed companies. This includes working with listed companies as a non-executive chair, non-executive director, general counsel, company secretary and in private practice.
Prior to joining LTR Pharma, Maja was general counsel and company secretary of US based Alexium International Group Limited (ASX:AJC).
Maja currently holds roles in multiple ASX listed companies, including non-executive chair of TechGen Metals (ASX.TG1), non-executive director of Kuniko (ASX.KNI), non-executive director of Indiana Resources Liimited (ASX.IDA).
